Table 3 Pathways significantly enriched (FDR <0.01) in lung focally exposed to high-dose radiation of 90 Gy using SPIA pathway analysis

5414

Dilated cardiomyopathy

3.23E-07

4.20E-05

4060

Cytokine-cytokine receptor interaction

1.91E-23

2.21E-21

4115

p53 signaling pathway

7.45E-10

3.43E-08

4060

Cytokine-cytokine receptor interaction

1.81E-12

2.37E-10

5030

Cocaine addiction

1.68E-05

1.09E-03

5150

Staphylococcus aureus infection

1.91E-17

1.11E-15

5202

Transcriptional misregulation in cancer

3.70E-05

8.51E-04

5414

Dilated cardiomyopathy

4.36E-10

2.86E-08

4740

Olfactory transduction

4.54E-05

1.96E-03

5140

Leishmaniasis

5.15E-17

1.99E-15

5218

Melanoma

2.65E-04

3.21E-03

5150

Staphylococcus aureus infection

2.19E-07

9.56E-06

5412

Arrhythmogenic right ventricular cardiomyopathy

9.17E-05

2.98E-03

5322

Systemic lupus erythematosus

8.35E-16

2.42E-14

5166

HTLV-I infection

2.79E-04

3.21E-03

5322

Systemic lupus erythematosus

6.35E-07

2.08E-05

4380

Osteoclast differentiation

6.38E-15

1.48E-13

5214

Glioma

4.27E-04

3.92E-03

5152

Tuberculosis

9.41E-07

2.47E-05

4062

Chemokine signaling pathway

7.48E-14

1.45E-12

5220

Chronic myeloid leukemia

6.01E-04

4.61E-03

4650

Natural killer cell mediated cytotoxicity

1.33E-06

2.87E-05

5152

Tuberculosis

9.50E-14

1.57E-12

4612

Antigen processing and presentation

1.53E-06

2.87E-05

4142

Lysosome

5.05E-13

7.33E-12

4062

Chemokine signaling pathway

2.85E-06

4.67E-05

5323

Rheumatoid arthritis

1.07E-12

1.37E-11

5030

Cocaine addiction

2.49E-05

3.62E-04

4612

Antigen processing and presentation

1.45E-12

1.69E-11

5140

Leishmaniasis

1.33E-04

1.73E-03

4650

Natural killer cell mediated cytotoxicity

1.94E-10

2.04E-09

5031

Amphetamine addiction

2.48E-04

2.95E-03

5310

Asthma

1.99E-09

1.92E-08

4020

Calcium signaling pathway

3.57E-04

3.60E-03

5330

Allograft rejection

2.31E-09

2.07E-08

5412

Arrhythmogenic right ventricular cardiomyopathy

3.57E-04

3.60E-03

5332

Graft-versus-host disease

2.58E-09

2.14E-08

4970

Salivary secretion

5.69E-04

5.32E-03

4940

Type I diabetes mellitus

9.98E-09

7.72E-08

5323

Rheumatoid arthritis

6.43E-04

5.61E-03

4672

Intestinal immune network for IgA production

2.96E-08

2.15E-07

5162

Measles

6.19E-08

4.23E-07

5164

Influenza A

1.14E-07

7.35E-07

5168

Herpes simplex infection

1.68E-07

1.03E-06

4660

T cell receptor signaling pathway

5.60E-07

3.25E-06

4610

Complement and coagulation cascades

1.29E-06

7.11E-06

5145

Toxoplasmosis

2.31E-06

1.22E-05

4064

NF-kappa B signaling pathway

2.43E-06

1.22E-05

5416

Viral myocarditis

4.68E-06

2.26E-05

4662

B cell receptor signaling pathway

1.46E-05

6.77E-05

5320

Autoimmune thyroid disease

2.37E-05

1.04E-04

4666

Fc gamma R-mediated phagocytosis

2.41E-05

1.04E-04

4620

Toll-like receptor signaling pathway

4.70E-05

1.95E-04

4670

Leukocyte transendothelial migration

7.56E-05

3.02E-04

5146

Amoebiasis

1.45E-04

5.62E-04

5142

Chagas disease

1.58E-04

5.90E-04

4630

Jak-STAT signaling pathway

1.71E-04

6.21E-04

5202

Transcriptional misregulation in cancer

1.81E-04

6.36E-04

4664

Fc epsilon RI signaling pathway

2.64E-04

9.01E-04

5133

Pertussis

2.87E-04

9.50E-04

5414

Dilated cardiomyopathy

1.13E-03

3.65E-03

4623

Cytosolic DNA-sensing pathway

1.28E-03

4.03E-03

ID

Name

P_G

FDR

ID

Name

P_G

FDR

ID

Name

P_G

FDR

ID

Name

P_G

FDR

NA

NA

NA

NA

4060

Cytokine-cytokine receptor interaction

5.49E-10

4.72E-08

4115

p53 signaling pathway

5.40E-05

1.08E-03

NA

NA

NA

NA

4620

Toll-like receptor signaling pathway

4.06E-08

1.74E-06

4062

Chemokine signaling pathway

2.81E-07

8.06E-06

5152

Tuberculosis

1.75E-06

3.77E-05

5323

Rheumatoid arthritis

3.60E-05

6.20E-04

5164

Influenza A

5.34E-05

7.65E-04

5162

Measles

6.80E-05

8.36E-04

4064

NF-kappa B signaling pathway

1.35E-04

1.45E-03

4660

T cell receptor signaling pathway

1.61E-04

1.54E-03

4142

Lysosome

5.08E-04

4.37E-03

4623

Cytosolic DNA-sensing pathway

6.69E-04

5.23E-03

5160

Hepatitis C

7.90E-04

5.65E-03

5168

Herpes simplex infection

9.39E-04

6.21E-03

4622

RIG-I-like receptor signaling pathway

1.21E-03

7.17E-03

5142

Chagas disease

1.25E-03

7.17E-03

5332

Graft-versus-host disease

1.79E-03

9.66E-03